In a report released yesterday, Shagun Singh Chadha from RBC Capital reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), ...
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...
The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...
Abbott Laboratories (NYSE:ABT – Get Free Report)‘s stock had its “outperform” rating reissued by equities researchers at Royal Bank of Canada in a report issued on Tuesday,Benzinga reports. They ...
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
BTIG analyst Marie Thibault maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...